Top

Published in:

01-12-2021 | Melanoma | Research article

Comparing the characteristics and predicting the survival of patients with head and neck melanoma versus body melanoma: a population-based study

Authors: Yuxin Ding, Runyi Jiang, Yuhong Chen, Jing Jing, Xiaoshuang Yang, Xianjie Wu, Xiaoyang Zhang, Jiali Xu, Piaopiao Xu, Shu Chen LiuHuang, Zhongfa Lu

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Previous studies reported cutaneous melanoma in head and neck (HNM) differed from those in other regions (body melanoma, BM). Individualized tools to predict the survival of patients with HNM or BM remain insufficient. We aimed at comparing the characteristics of HNM and BM, developing and validating nomograms for predicting the survival of patients with HNM or BM.

Methods

The information of patients with HNM or BM from 2004 to 2015 was obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The HNM group and BM group were randomly divided into training and validation cohorts. We used the Kaplan-Meier method and multivariate Cox models to identify independent prognostic factors. Nomograms were developed via the rms and dynnom packages, and were measured by the concordance index (C-index), the area under the curve (AUC) of the receiver operating characteristic (ROC) curve and calibration plots.

Results

Of 70,605 patients acquired, 21% had HNM and 79% had BM. The HNM group contained more older patients, male sex and lentigo maligna melanoma, and more frequently had thicker tumors and metastases than the BM group. The 5-year cancer-specific survival (CSS) and overall survival (OS) rates were 88.1 ± 0.3% and 74.4 ± 0.4% in the HNM group and 92.5 ± 0.1% and 85.8 ± 0.2% in the BM group, respectively. Eight variables (age, sex, histology, thickness, ulceration, stage, metastases, and surgery) were identified to construct nomograms of CSS and OS for patients with HNM or BM. Additionally, four dynamic nomograms were available on web. The internal and external validation of each nomogram showed high C-index values (0.785–0.896) and AUC values (0.81–0.925), and the calibration plots showed great consistency.

Conclusions

The characteristics of HNM and BM are heterogeneous. We constructed and validated four nomograms for predicting the 3-, 5- and 10-year CSS and OS probabilities of patients with HNM or BM. These nomograms can serve as practical clinical tools for survival prediction and individual health management.

Available only for authorised users

Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet. 2018;392(10151):971–84. https://doi.org/10.1016/s0140-6736(18)31559-9.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.CrossRefPubMed

Garbe C, Büttner P, Bertz J, Burg G, d’Hoedt B, Drepper H, et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer. 1995;75(10):2492–8. https://doi.org/10.1002/1097-0142(19950515)75:10<2492::aid-cncr2820751015>3.0.co;2-w.

Callender G, Egger M, Burton A, Scoggins C, Ross M, Stromberg A, et al. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker. Am J Surg. 2011;202(6):659–65. https://doi.org/10.1016/j.amjsurg.2011.06.048.CrossRefPubMed

Howard MD, Wee E, Wolfe R, McLean CA, Kelly JW, Pan Y. Anatomic location of primary melanoma: survival differences and sun exposure. J Am Acad Dermatol. 2019;81(2):500–9. https://doi.org/10.1016/j.jaad.2019.04.034.CrossRefPubMed

Garbe C, Büttner P, Bertz J, Burg G, d'Hoedt B, Drepper H, et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer. 1995;75(10):2484–91. https://doi.org/10.1002/1097-0142(19950515)75:10<2484::aid-cncr2820751014>3.0.co;2-u.

Gillgren P, Månsson-Brahme E, Frisell J, Johansson H, Larsson O, Ringborg U. Epidemiological characteristics of cutaneous malignant melanoma of the head and neck--a population-based study. Acta Oncol. 1999;38(8):1069–74. https://doi.org/10.1080/028418699432383.CrossRefPubMed

Lesage C, Barbe C, Le Clainche A, Lesage FX, Bernard P, Grange F. Sex-related location of head and neck melanoma strongly argues for a major role of sun exposure in cars and photoprotection by hair. J Invest Dermatol. 2013;133(5):1205–11. https://doi.org/10.1038/jid.2012.405.CrossRefPubMed

Dabouz F, Barbe C, Lesage C, Le Clainche A, Arnoult G, Hibon E, et al. Clinical and histological features of head and neck melanoma: a population-based study in France. Br J Dermatol. 2015;172(3):707–15. https://doi.org/10.1111/bjd.13489.CrossRefPubMed

10.

Juzeniene A, Micu E, Porojnicu A, Moan J. Malignant melanomas on head/neck and foot: differences in time and latitudinal trends in Norway. J Eur Acad Dermatol Venereol. 2012;26(7):821–7. https://doi.org/10.1111/j.1468-3083.2011.04162.x.CrossRefPubMed

11.

Ghiasvand R, Robsahm T, Green A, Rueegg C, Weiderpass E, Lund E, et al. Association of Phenotypic Characteristics and UV radiation exposure with risk of melanoma on different body sites. JAMA Dermatol. 2019;155(1):39–49. https://doi.org/10.1001/jamadermatol.2018.3964.CrossRefPubMed

12.

Tseng W, Martinez S. Tumor location predicts survival in cutaneous head and neck melanoma. J Surg Res. 2011;167(2):192–8. https://doi.org/10.1016/j.jss.2010.10.008.CrossRefPubMed

13.

de Giorgi V, Rossari S, Gori A, Grazzini M, Savarese I, Crocetti E, et al. The prognostic impact of the anatomical sites in the 'head and neck melanoma': scalp versus face and neck. Melanoma Res. 2012;22(5):402–5. https://doi.org/10.1097/CMR.0b013e3283577b96.

14.

Helsing P, Robsahm TE, Vos L, Rizvi SM, Akslen LA, Veierod MB. Cutaneous head and neck melanoma (CHNM): a population-based study of the prognostic impact of tumor location. J Am Acad Dermatol. 2016;75(5):975–82. https://doi.org/10.1016/j.jaad.2016.06.048.CrossRefPubMed

15.

Shi K, Camilon PR, Roberts JM, Meier JD. Survival differences between pediatric head and neck versus body melanoma in the Surveillance, epidemiology, and end results program. Laryngoscope. 2020;131(2):E635–41. https://doi.org/10.1002/lary.28711.CrossRefPubMed

16.

Hoersch B, Leiter U, Garbe CJ. Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. Br J Dermatol. 2006;155(4):771–7. https://doi.org/10.1111/j.1365-2133.2006.07455.x.CrossRefPubMed

17.

Ringborg U, Afzelius L, Lagerlöf B, Adami H, Augustsson I, Blomqvist E, et al. Cutaneous malignant melanoma of the head and neck. Analysis of treatment results and prognostic factors in 581 patients: a report from the Swedish melanoma study group. Cancer. 1993;71(3):751–8. https://doi.org/10.1002/1097-0142(19930201)71:3<751::aid-cncr2820710317>3.0.co;2-9.

18.

Xie C, Pan Y, McLean C, Mar V, Wolfe R, Kelly J. Impact of scalp location on survival in head and neck melanoma: a retrospective cohort study. J Am Acad Dermatol. 2017;76(3):494–8 e2. https://doi.org/10.1016/j.jaad.2016.08.009.CrossRefPubMed

19.

Gulati M, Black H, Shaw L, Arnsdorf M, Merz C, Lauer M, et al. The prognostic value of a nomogram for exercise capacity in women. N Engl J Med. 2005;353(5):468–75. https://doi.org/10.1056/NEJMoa044154.CrossRefPubMed

20.

Huang Y, Liang C, He L, Tian J, Liang C, Chen X, et al. Development and validation of a Radiomics Nomogram for preoperative prediction of lymph node metastasis in colorectal Cancer. J Clin Oncol. 2016;34(18):2157–64. https://doi.org/10.1200/jco.2015.65.9128.

21.

Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol. 2007;25(31):4952–60. https://doi.org/10.1200/JCO.2006.08.0499.

22.

Berardi G, Morise Z, Sposito C, Igarashi K, Panetta V, Simonelli I, et al. Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in child-Pugh B cirrhosis. J Hepatol. 2020;72(1):75–84. https://doi.org/10.1016/j.jhep.2019.08.032.

23.

Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Custom Data (with additional treatment fields), Nov 2018 Sub (1975–2016 varying) - Linked To County Attributes - Total U.S., 1969–2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission. [database on the Internet]. Available from: www.seer.cancer.gov. Accessed: April 2019.

24.

Rachidi S, Deng Z, Sullivan DY, Lipson EJ. Shorter survival and later stage at diagnosis among unmarried patients with cutaneous melanoma: a US national and tertiary care center study. J Am Acad Dermatol. 2020;83(4):1012–20. https://doi.org/10.1016/j.jaad.2020.05.088.CrossRefPubMed

25.

Shen W, Sakamoto N, Yang L. Melanoma-specific mortality and competing mortality in patients with non-metastatic malignant melanoma: a population-based analysis. BMC Cancer. 2016;16(1):413. https://doi.org/10.1186/s12885-016-2438-3.CrossRefPubMedPubMedCentral

26.

Liu H, Xu YB, Guo CC, Li MX, Ji JL, Dong RR, et al. Predictive value of a nomogram for melanomas with brain metastases at initial diagnosis. Cancer Med. 2019;8(18):7577–85. https://doi.org/10.1002/cam4.2644.

27.

Lachiewicz A, Berwick M, Wiggins C, Thomas N. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, epidemiology, and end results (SEER) program. Arch Dermatol. 2008;144(4):515–21. https://doi.org/10.1001/archderm.144.4.515.CrossRefPubMed

28.

Xiao Y, Peng S, Hu Y, Zhang J, Cao X. Development and validation of prognostic nomogram in patients with nonmetastatic malignant melanoma: a SEER population-based study. Cancer Med. 2020;9(22):8562–70. https://doi.org/10.1002/cam4.3318.CrossRefPubMedPubMedCentral

29.

Surveillance Research Program, National Cancer Institute SEER*Stat software version 8.3.8. www.seer.cancer.gov/seerstat. Accessed 2 Sept 2020.

30.

Camp R, Dolled-Filhart M, Rimm D. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–9. https://doi.org/10.1158/1078-0432.Ccr-04-0713.CrossRefPubMed

31.

Gershenwald J, Scolyer R, Hess K, Sondak V, Long G, Ross M, et al. Melanoma staging: evidence-based changes in the American joint committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–92. https://doi.org/10.3322/caac.21409.CrossRefPubMedPubMedCentral

32.

Claeson M, Baade P, Brown S, Soyer HP, Smithers BM, Green AC, et al. Clinicopathological factors associated with death from thin (</= 1.00 mm) melanoma. Br J Dermatol. 2020;182(4):927–31. https://doi.org/10.1111/bjd.18560.

33.

Dynamic HNM nomogram, CSS. https://melanomanomogram.shinyapps.io/csshnm/. Accessed 17 Mar 2021.

34.

Dynamic BM nomogram, CSS. https://melanomanomogram.shinyapps.io/cssbm/. Accessed 17 Mar 2021.

35.

Dynamic HNM nomogram, OS. https://melanomanomogram.shinyapps.io/oshnm/. Accessed 17 March 2021.

36.

Dynamic BM nomogram, OS. https://melanomanomogram.shinyapps.io/osbm/. Accessed 17 Mar 2021.

37.

MacKie R, Bray C, Vestey J, Doherty V, Evans A, Thomson D, et al. Melanoma incidence and mortality in Scotland 1979-2003. Br J Cancer. 2007;96(11):1772–7. https://doi.org/10.1038/sj.bjc.6603801.CrossRefPubMedPubMedCentral

38.

Ciocan D, Barbe C, Aubin F, Granel-Brocard F, Lipsker D, Velten M, et al. Distinctive features of melanoma and its management in elderly patients: a population-based study in France. JAMA Dermatol. 2013;149(10):1150–7. https://doi.org/10.1001/jamadermatol.2013.706.

39.

Stanienda-Sokół K, Salwowska N, Sławińska M, Wicherska-Pawłowska K, Lorenc A, Wcisło-Dziadecka D, et al. Primary locations of malignant melanoma lesions depending on patients’ gender and age. Asian Pac J Cancer Prev. 2017;18(11):3081–6. https://doi.org/10.22034/apjcp.2017.18.11.3081.CrossRefPubMedPubMedCentral

40.

Kemeny M, Busch E, Stewart A, Menck H. Superior survival of young women with malignant melanoma. Am J Surg. 1998;175(6):437–44; discussion 44-5. https://doi.org/10.1016/s0002-9610(98)00070-1.CrossRefPubMed

41.

Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I, et al. The advantage of women in cancer survival: an analysis of EUROCARE-4 data. Eur J Cancer. 2009;45(6):1017–27. https://doi.org/10.1016/j.ejca.2008.11.008.

42.

Ossio R, Roldán-Marín R, Martínez-Said H, Adams D, Robles-Espinoza C. Melanoma: a global perspective. Nat Rev Cancer. 2017;17(7):393–4. https://doi.org/10.1038/nrc.2017.43.CrossRefPubMed

43.

Allais B, Beatson M, Wang H, Shahbazi S, Bijelic L, Jang S, et al. Five-year survival in patients with nodular and superficial spreading melanomas in the US population. J Am Acad Dermatol. 2020;84(4):1015–22. https://doi.org/10.1016/j.jaad.2020.11.047.CrossRefPubMed

44.

Gandini S, Sera F, Cattaruzza M, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41(1):45–60. https://doi.org/10.1016/j.ejca.2004.10.016.CrossRefPubMed

45.

Whiteman D, Stickley M, Watt P, Hughes M, Davis M, Green A. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol. 2006;24(19):3172–7. https://doi.org/10.1200/jco.2006.06.1325.CrossRefPubMed

46.

Saaiq M, Zalaudek I, Rao B, Lee Y, Rudnicka L, Czuwara J, et al. A brief synopsis on scalp melanoma. Dermatol Ther. 2020;33(4):e13795. https://doi.org/10.1111/dth.13795.

47.

Eggermont A, Spatz A, Robert C. Cutaneous melanoma. Lancet. 2014;383(9919):816–27. https://doi.org/10.1016/s0140-6736(13)60802-8.CrossRefPubMed

48.

DeSantis C, Miller K, Dale W, Mohile S, Cohen H, Leach C, et al. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J Clin. 2019;69(6):452–67. https://doi.org/10.3322/caac.21577.CrossRefPubMed

49.

Kienstra M, Padhya T. Head and neck melanoma. Cancer Control. 2005;12(4):242–7. https://doi.org/10.1177/107327480501200406.CrossRefPubMed

Title: Comparing the characteristics and predicting the survival of patients with head and neck melanoma versus body melanoma: a population-based study
Authors: Yuxin Ding
Runyi Jiang
Yuhong Chen
Jing Jing
Xiaoshuang Yang
Xianjie Wu
Xiaoyang Zhang
Jiali Xu
Piaopiao Xu
Shu Chen LiuHuang
Zhongfa Lu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Melanoma
Melanoma
Lentigo Maligna Melanoma
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08105-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition

Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs

Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients

A novel scoring system integrating molecular abnormalities with IPSS-R can improve the risk stratification in patients with MDS

Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study

Development and validation of a survival nomogram for patients with Siewert type II/III adenocarcinoma of the esophagogastric junction based on real-world data

Keynote webinar | Spotlight on antibody–drug conjugates in cancer